BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34586875)

  • 1. The Current Status of Latency Reversing Agents for HIV-1 Remission.
    Rodari A; Darcis G; Van Lint CM
    Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell biology of HIV-1 latency and rebound.
    Mbonye U; Karn J
    Retrovirology; 2024 Apr; 21(1):6. PubMed ID: 38580979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency.
    Rodari A; Poli G; Van Lint C
    Methods Mol Biol; 2022; 2407():3-15. PubMed ID: 34985653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling HIV-1 Latency Using Primary CD4
    Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.
    Duggan NN; Dragic T; Chanda SK; Pache L
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
    Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; Cruz CRY; Jones RB; Lynch RM; Sweeney EE; Fernandes R
    Int J Nanomedicine; 2023; 18():4055-4066. PubMed ID: 37520301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Latency: Should We Shock or Lock?
    Darcis G; Van Driessche B; Van Lint C
    Trends Immunol; 2017 Mar; 38(3):217-228. PubMed ID: 28073694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
    Siliciano JD; Siliciano RF
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4
    Battivelli E; Dahabieh MS; Abdel-Mohsen M; Svensson JP; Tojal Da Silva I; Cohn LB; Gramatica A; Deeks S; Greene WC; Pillai SK; Verdin E
    Elife; 2018 May; 7():. PubMed ID: 29714165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
    Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
    J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.